Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-15
    E.g., 2018-10-15

Archive Search

1 results
10:38 PM, May 11, 2017  |  BC Week In Review | Clinical News  |  Clinical Results

Braeburn’s BB0817 risperidone implant meets Phase II/III PK endpoint

data from a Phase II/III trial in more than 50 stabilized schizophrenic patients showing that BB0817
the active metabolite of risperidone -- over 6 months to that of oral risperidone. BB0817
on once-daily 4 mg oral risperidone for ≥8 weeks to receive three 300 mg subcutaneous BB0817